Among 15 patients with relapsed ALCL after the failure of brentuximab vedotin therapy, the ALK inhibitor brigatinib led to a complete response in 73%, and progression-free survival at 2 years was 73%.
The New England Journal of Medicine: Search Results in Hematology/Oncology
